Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.72 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.61 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.61 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.61 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.61 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826721 | 0.94 | MAPT (0.83) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL4286068 | 0.91 | MAPT (0.94) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL4517587 | 0.86 | LMNA (1.00) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL30739929 | 0.86 | LMNA (1.00) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL4656855 | 0.85 | MAPT (0.78) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL2494871 | 0.85 | KCNK3 (0.81) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL15094033 | 0.85 | MAPT (0.78) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL29800565 | 0.84 | MEN1 (0.93) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL6793906 | 0.84 | MEN1 (0.93) | MEN1KMT2AMAPTLMNARAB9A | |
| SCHEMBL11675529 | 0.84 | MEN1 (1.00) | MEN1KMT2AMAPTLMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| EP-3647313-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Xiamen University (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | MEN1 1374/4885KMT2A 799/4885MAPT 3529/4885 |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | MEN1 627/4885KMT2A 974/4885MAPT 4439/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | MEN1 1374/4885KMT2A 799/4885MAPT 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.